Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.

British journal of clinical pharmacology - 1 Jan 2008

Kalliokoski Annikka, Neuvonen Mikko, Neuvonen Pertti J, Niemi Mikko

Abstract excerpt

AIMS: To examine possible effects of polymorphism in the SLCO1B1 gene, encoding the hepatic uptake transporter organic anion transporting polypeptide (OATP) 1B1, on the pharmacokinetics of rosiglitazone and pioglitazone in a prospective genotype panel study. METHODS: Sixteen healthy volunteers with the homozygous SLCO1B1 c.521TT genotype (controls), 12 with the heterozygous c.521TC genotype and four with the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cross-Over Studies
Share to Hypoglycemic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver-Specific Organic Anion Transporter 1

Share to Organic Anion Transporters

Share to Pioglitazone

Share to Polymorphism, Genetic

Share to Rosiglitazone

Share to Thiazolidinediones

Source

Open in PubMed Open full text

Identifiers

PMID: 17635496
DOI: 10.1111/j.1365-2125.2007.02986.x
PMCID: PMC2291278

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.PMID 17635496Read ↗

Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers.Semantic proximity Read ↗

SLCO1B1 polymorphism and oral antidiabetic drugs.Semantic proximity Read ↗

A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics.Semantic proximity Read ↗

Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.Semantic proximity Read ↗

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.Semantic proximity Read ↗

Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.Semantic proximity Read ↗

Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers.Semantic proximity Read ↗

Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide.Semantic proximity Read ↗

CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes.Semantic proximity Read ↗

Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions.Semantic proximity Read ↗

No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.Semantic proximity Read ↗

The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.